Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Feb;41(2):278–283. doi: 10.1128/aac.41.2.278

A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques.

K K Van Rompay 1, J L Greenier 1, M L Marthas 1, M G Otsyula 1, R P Tarara 1, C J Miller 1, N C Pedersen 1
PMCID: PMC163702  PMID: 9021180

Abstract

The simian immunodeficiency virus (SIV)-newborn rhesus macaque model of AIDS can be used to study directly the virulence of viral mutants which are resistant to antiviral drugs. A viral mutant called SIVmac79A6.1, isolated from an SIV-infected macaque after prolonged zidovudine treatment, was found to have a double-base-pair change at codon 151 of reverse transcriptase, resulting in a glutamine to methionine substitution (Q151M). This mutation was associated with more than 100-fold increased resistance to zidovudine and low-level cross-resistance to other dideoxynucleoside analogs. To determine whether this Q151M mutation affects viral virulence, four newborn macaques were inoculated intravenously with a biological clone of this drug-resistant SIVmac79A6.1 mutant; two of these animals were also treated orally with zidovudine. All four animals showed persistent viremia, and two of the four animals developed fatal immunodeficiency at 3 and 8 months of age, respectively. The remaining two animals had CD4+ T-cell depletion and clinical symptoms of AIDS at 22 months. No phenotypic or genotypic reversion of virus to the wild type could be detected in any of the four animals. These results demonstrate that the Q151M mutation in SIV reverse transcriptase does not reduce viral virulence.

Full Text

The Full Text of this article is available as a PDF (213.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ammann A. J. Human immunodeficiency virus infection/AIDS in children: the next decade. Pediatrics. 1994 Jun;93(6 Pt 1):930–935. [PubMed] [Google Scholar]
  2. Angarano G., Monno L., Appice A., Giannelli A., Romanelli C., Fico C., Pastore G. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. AIDS. 1994 Jul;8(7):1013–1014. doi: 10.1097/00002030-199407000-00023. [DOI] [PubMed] [Google Scholar]
  3. Boucher C. A., van Leeuwen R., Kellam P., Schipper P., Tijnagel J., Lange J. M., Larder B. A. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1993 Jul;37(7):1525–1530. doi: 10.1128/aac.37.7.1525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boyer P. L., Ferris A. L., Clark P., Whitmer J., Frank P., Tantillo C., Arnold E., Hughes S. H. Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase. J Mol Biol. 1994 Oct 28;243(3):472–483. doi: 10.1006/jmbi.1994.1673. [DOI] [PubMed] [Google Scholar]
  5. Cheeseman S. H., Havlir D., McLaughlin M. M., Greenough T. C., Sullivan J. L., Hall D., Hattox S. E., Spector S. A., Stein D. S., Myers M. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):141–151. [PubMed] [Google Scholar]
  6. D'Aquila R. T., Johnson V. A., Welles S. L., Japour A. J., Kuritzkes D. R., DeGruttola V., Reichelderfer P. S., Coombs R. W., Crumpacker C. S., Kahn J. O. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995 Mar 15;122(6):401–408. doi: 10.7326/0003-4819-122-6-199503150-00001. [DOI] [PubMed] [Google Scholar]
  7. Erice A., Balfour H. H., Jr Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin Infect Dis. 1994 Feb;18(2):149–156. doi: 10.1093/clinids/18.2.149. [DOI] [PubMed] [Google Scholar]
  8. Erice A., Mayers D. L., Strike D. G., Sannerud K. J., McCutchan F. E., Henry K., Balfour H. H., Jr Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993 Apr 22;328(16):1163–1165. doi: 10.1056/NEJM199304223281605. [DOI] [PubMed] [Google Scholar]
  9. Frenkel L. M., Wagner L. E., 2nd, Demeter L. M., Dewhurst S., Coombs R. W., Murante B. L., Reichman R. C. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995 May;20(5):1321–1326. doi: 10.1093/clinids/20.5.1321. [DOI] [PubMed] [Google Scholar]
  10. Hermans P., Sprecher S., Clumeck N. Primary infection with zidovudine-resistant HIV. N Engl J Med. 1993 Oct 7;329(15):1123–1124. doi: 10.1056/NEJM199310073291514. [DOI] [PubMed] [Google Scholar]
  11. Iversen A. K., Shafer R. W., Wehrly K., Winters M. A., Mullins J. I., Chesebro B., Merigan T. C. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol. 1996 Feb;70(2):1086–1090. doi: 10.1128/jvi.70.2.1086-1090.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Johnson V. A. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J Infect Dis. 1995 Mar;171 (Suppl 2):S140–S149. doi: 10.1093/infdis/171.supplement_2.s140. [DOI] [PubMed] [Google Scholar]
  13. Kellam P., Boucher C. A., Larder B. A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1934–1938. doi: 10.1073/pnas.89.5.1934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kuritzkes D. R., Bell S., Bakhtiari M. Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1. AIDS. 1994 Jul;8(7):1017–1019. [PubMed] [Google Scholar]
  15. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  16. Lohman B. L., Higgins J., Marthas M. L., Marx P. A., Pedersen N. C. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J Clin Microbiol. 1991 Oct;29(10):2187–2192. doi: 10.1128/jcm.29.10.2187-2192.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Marthas M. L., van Rompay K. K., Otsyula M., Miller C. J., Canfield D. R., Pedersen N. C., McChesney M. B. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol. 1995 Jul;69(7):4198–4205. doi: 10.1128/jvi.69.7.4198-4205.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Masquelier B., Lemoigne E., Pellegrin I., Douard D., Sandler B., Fleury H. J. Primary infection with zidovudine-resistant HIV. N Engl J Med. 1993 Oct 7;329(15):1123–1124. [PubMed] [Google Scholar]
  19. Montaner J. S., Singer J., Schechter M. T., Raboud J. M., Tsoukas C., O'Shaughnessy M., Ruedy J., Nagai K., Salomon H., Spira B. Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS. 1993 Feb;7(2):189–196. doi: 10.1097/00002030-199302000-00006. [DOI] [PubMed] [Google Scholar]
  20. Nielsen K., Wei L. S., Sim M. S., Deveikis A., Keller M., Stiehm E. R., Frenkel L. M., Bryson Y. J. Correlation of clinical progression in human immunodeficiency virus-infected children with in vitro zidovudine resistance measured by a direct quantitative peripheral blood lymphocyte assay. J Infect Dis. 1995 Aug;172(2):359–364. doi: 10.1093/infdis/172.2.359. [DOI] [PubMed] [Google Scholar]
  21. Ogino M. T., Dankner W. M., Spector S. A. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. J Pediatr. 1993 Jul;123(1):1–8. doi: 10.1016/s0022-3476(05)81529-x. [DOI] [PubMed] [Google Scholar]
  22. Otsyula M. G., Miller C. J., Marthas M. L., Van Rompay K. K., Collins J. R., Pedersen N. C., McChesney M. B. Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus. Pediatr Res. 1996 Apr;39(4 Pt 1):630–635. doi: 10.1203/00006450-199604000-00012. [DOI] [PubMed] [Google Scholar]
  23. Richman D. D. Clinical significance of drug resistance in human immunodeficiency virus. Clin Infect Dis. 1995 Oct;21 (Suppl 2):S166–S169. doi: 10.1093/clinids/21.supplement_2.s166. [DOI] [PubMed] [Google Scholar]
  24. Richman D. D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S. A., Sullivan J., Cheeseman S., Barringer K., Pauletti D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994 Mar;68(3):1660–1666. doi: 10.1128/jvi.68.3.1660-1666.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Richman D. D. Human immunodeficiency virus. Protease uninhibited. Nature. 1995 Apr 6;374(6522):494–494. doi: 10.1038/374494a0. [DOI] [PubMed] [Google Scholar]
  26. Richman D. D. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother. 1993 Jun;37(6):1207–1213. doi: 10.1128/aac.37.6.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Richman D. D. Resistance, drug failure, and disease progression. AIDS Res Hum Retroviruses. 1994 Aug;10(8):901–905. doi: 10.1089/aid.1994.10.901. [DOI] [PubMed] [Google Scholar]
  28. Saag M. S., Emini E. A., Laskin O. L., Douglas J., Lapidus W. I., Schleif W. A., Whitley R. J., Hildebrand C., Byrnes V. W., Kappes J. C. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med. 1993 Oct 7;329(15):1065–1072. doi: 10.1056/NEJM199310073291502. [DOI] [PubMed] [Google Scholar]
  29. Schmit J. C., Cogniaux J., Hermans P., Van Vaeck C., Sprecher S., Van Remoortel B., Witvrouw M., Balzarini J., Desmyter J., De Clercq E. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis. 1996 Nov;174(5):962–968. doi: 10.1093/infdis/174.5.962. [DOI] [PubMed] [Google Scholar]
  30. Shafer R. W., Iversen A. K., Winters M. A., Aguiniga E., Katzenstein D. A., Merigan T. C. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis. 1995 Jul;172(1):70–78. doi: 10.1093/infdis/172.1.70. [DOI] [PubMed] [Google Scholar]
  31. Shafer R. W., Kozal M. J., Winters M. A., Iversen A. K., Katzenstein D. A., Ragni M. V., Meyer W. A., 3rd, Gupta P., Rasheed S., Coombs R. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994 Apr;169(4):722–729. doi: 10.1093/infdis/169.4.722. [DOI] [PubMed] [Google Scholar]
  32. Shirasaka T., Kavlick M. F., Ueno T., Gao W. Y., Kojima E., Alcaide M. L., Chokekijchai S., Roy B. M., Arnold E., Yarchoan R. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2398–2402. doi: 10.1073/pnas.92.6.2398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Shirasaka T., Yarchoan R., O'Brien M. C., Husson R. N., Anderson B. D., Kojima E., Shimada T., Broder S., Mitsuya H. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):562–566. doi: 10.1073/pnas.90.2.562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Siegrist C. A., Yerly S., Kaiser L., Wyler C. A., Perrin L. Mother to child transmission of zidovudine-resistant HIV-1. Lancet. 1994 Dec 24;344(8939-8940):1771–1772. [PubMed] [Google Scholar]
  35. Sutjipto S., Pedersen N. C., Miller C. J., Gardner M. B., Hanson C. V., Gettie A., Jennings M., Higgins J., Marx P. A. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J Virol. 1990 May;64(5):2290–2297. doi: 10.1128/jvi.64.5.2290-2297.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sönnerburg A., Johansson B., Ayehunie S., Julander I. Transmission of zidovudine-resistant HIV-1. AIDS. 1993 Dec;7(12):1684–1685. doi: 10.1097/00002030-199312000-00027. [DOI] [PubMed] [Google Scholar]
  37. Tudor-Williams G., St Clair M. H., McKinney R. E., Maha M., Walter E., Santacroce S., Mintz M., O'Donnell K., Rudoll T., Vavro C. L. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet. 1992 Jan 4;339(8784):15–19. doi: 10.1016/0140-6736(92)90140-x. [DOI] [PubMed] [Google Scholar]
  38. Ueno T., Shirasaka T., Mitsuya H. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates. J Biol Chem. 1995 Oct 6;270(40):23605–23611. doi: 10.1074/jbc.270.40.23605. [DOI] [PubMed] [Google Scholar]
  39. Van Rompay K. K., Cherrington J. M., Marthas M. L., Berardi C. J., Mulato A. S., Spinner A., Tarara R. P., Canfield D. R., Telm S., Bischofberger N. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother. 1996 Nov;40(11):2586–2591. doi: 10.1128/aac.40.11.2586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Van Rompay K. K., Marthas M. L., Ramos R. A., Mandell C. P., McGowan E. K., Joye S. M., Pedersen N. C. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother. 1992 Nov;36(11):2381–2386. doi: 10.1128/aac.36.11.2381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Van Rompay K. K., Otsyula M. G., Marthas M. L., Miller C. J., McChesney M. B., Pedersen N. C. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother. 1995 Jan;39(1):125–131. doi: 10.1128/aac.39.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Van Rompay K. K., Otsyula M. G., Tarara R. P., Canfield D. R., Berardi C. J., McChesney M. B., Marthas M. L. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J Infect Dis. 1996 Jun;173(6):1327–1335. doi: 10.1093/infdis/173.6.1327. [DOI] [PubMed] [Google Scholar]
  43. Wainberg M. A., Gu Z., Gao Q., Arts E., Geleziunas R., Bour S., Beaulieu R., Tsoukas C., Singer J., Montaner J. Clinical correlates and molecular basis of HIV drug resistance. J Acquir Immune Defic Syndr. 1993;6 (Suppl 1):S36–S46. [PubMed] [Google Scholar]
  44. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES